Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon H Chung

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Journal of the National Cancer Institute|June 10, 2020
Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder CancerMarco Bandini, Jeffrey S Ross, Daniele Raggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or AnusAlexa B Schrock, Dean Pavlick, Samuel J Klempner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II StudyAndrea Necchi, Andrea Anichini, Daniele Raggi, et al.
European Urology Focus|July 21, 2018
Genomic Characterization of Testicular Germ Cell Tumors Relapsing After ChemotherapyAndrea Necchi, Gennady Bratslavsky, Robert J Corona, et al.
Clinical Genitourinary Cancer|March 8, 2020
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional StudyMarco Bandini, Filippo Pederzoli, Russell Madison, et al.
European Urology|November 12, 2019
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant HistologiesAndrea Necchi, Daniele Raggi, Andrea Gallina, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Nature Communications|November 18, 2018
RET rearrangements are actionable alterations in breast cancerBhavna S Paratala, Jon H Chung, Casey B Williams, et al.
European Urology|December 29, 2019
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 StudyAndrea Necchi, Marco Bandini, Giuseppina Calareso, et al.
JCO Precision Oncology|February 9, 2022
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational StudySteven F Powell, Elie G Dib, Jonathan S Bleeker, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of the National Cancer Institute|June 10, 2020
Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder CancerMarco Bandini, Jeffrey S Ross, Daniele Raggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or AnusAlexa B Schrock, Dean Pavlick, Samuel J Klempner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II StudyAndrea Necchi, Andrea Anichini, Daniele Raggi, et al.
European Urology Focus|July 21, 2018
Genomic Characterization of Testicular Germ Cell Tumors Relapsing After ChemotherapyAndrea Necchi, Gennady Bratslavsky, Robert J Corona, et al.
Clinical Genitourinary Cancer|March 8, 2020
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional StudyMarco Bandini, Filippo Pederzoli, Russell Madison, et al.
European Urology|November 12, 2019
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant HistologiesAndrea Necchi, Daniele Raggi, Andrea Gallina, et al.
Journal of Gastrointestinal Oncology|October 12, 2019
Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsyGerald Li, Dean Pavlick, Jon H Chung, et al.
Nature Communications|November 18, 2018
RET rearrangements are actionable alterations in breast cancerBhavna S Paratala, Jon H Chung, Casey B Williams, et al.
European Urology|December 29, 2019
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 StudyAndrea Necchi, Marco Bandini, Giuseppina Calareso, et al.
JCO Precision Oncology|February 9, 2022
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational StudySteven F Powell, Elie G Dib, Jonathan S Bleeker, et al.
Pageof 5